<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971253</url>
  </required_header>
  <id_info>
    <org_study_id>015K-MA-3311</org_study_id>
    <nct_id>NCT03971253</nct_id>
  </id_info>
  <brief_title>Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the safety and effectiveness in routine
      clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA)
      treated with peficitinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a mandatory Post-Marketing Surveillance (PMS) requested by Pharmaceuticals and
      Medical Devices Agency (PMDA) as a part of the Japan-Risk Management Plan (J-RMP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by frequency of adverse events (AEs)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An AE is defined as any unwanted medical occurrence after drug administration and which does not necessarily have a causal relationship with the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by frequency of adverse drug reactions (ADRs)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>AEs whose relationship to the study drugs could not be ruled out is considered adverse drug reaction. AEs that fall under either &quot;Probable&quot; or &quot;Possible&quot; or &quot;Unassessable&quot; should be defined as &quot;AEs whose relationship to the study drugs could not be ruled out.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by frequency of serious infections</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>Serious infections include tuberculosis, pneumonia, pneumocystis pneumonia, ichorrhemia and opportunistic infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by frequency of malignancy</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>Frequency of malignancy found after drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by frequency of events leading to death</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>Any events leading to death will be reported as serious AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by frequency of AEs of special interests</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>AEs of special interests include neutrophil decrease, lymphocyte decrease, hemoglobin decrease, Herpes zoster, gastrointestinal perforation, interstitial pneumonia, reactivation of Hepatitis B virus, hepatic function disorder, cardiovascular events, rhabdomyolysis and myopathy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by frequency of serious adverse events (SAEs)</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>An AE is considered &quot;serious&quot; if, in the view of either the investigator, it results in any of the following outcomes: death, life-threatening, persistent or significant disability/incapacity or substantial disruption, congenital anomaly or birth defect, hospitalization or prolongation of hospitalization, or medically important events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by frequency of serious adverse drug reactions (SADRs)</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>SAEs whose relationship to the study drugs could not be ruled out is considered serious ADR. SAEs that fall under either &quot;Probable&quot; or &quot;Possible&quot; or &quot;Unassessable&quot; should be defined as &quot;SAEs whose relationship to the study drugs could not be ruled out.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity score (DAS28) - C-reactive protein (CRP)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>DAS28-CRP will be calculated using data from Tender Joint Count (TJC) (28 joints), Swollen Joint Count (SJC) (28 joints), C-reactive protein (CRP) and Subject's Global Assessment of Arthritis (SGA) with the formula; DAS28-CRP = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP (mg/dL) x 10 + 1) + 0.014 x SGA (mm) + 0.96.
DAS28-CRP exceeding 5.1 is considered high disease activity; exceeding 3.2 and not greater than 5.1, moderate disease activity; exceeding 2.6 and not greater than 3.2, low disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DAS28- erythrocyte sedimentation rate (ESR) score</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR (mm/h) + 0.014 x SGA (mm).
DAS28-ESR exceeding 5.1 is considered high disease activity; exceeding 3.2 and not greater than 5.1, moderate disease activity; exceeding 2.6 and not greater than 3.2, low disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Simplified Disease Activity Index (SDAI) score</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>SDAI score will be calculated with formula SDAI = TJC + SJC + SGA + Physician's Global Assessment of Arthritis (PGA) + CRP.
SDAI score exceeding 26 is considered high disease activity; exceeding 11 and not greater than 26, moderate disease activity; exceeding 3.3 and not greater than 11, low disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) score</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>CDAI score will be calculated with formula CDAI = TJC + SJC + SGA + PGA. CDAI score exceeding 22 is considered high disease activity; exceeding 10 and not greater than 22, moderate disease activity; exceeding 2.8 and not greater than 10, low disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tender Joint Count (TJC) (28 joints)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The investigator/sub-investigator will examine the participant for tender joints, assessing the 28 joints and confirm the location of each tender joint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swollen Joint Count (SJC) (28 joints)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The investigator/sub-investigator will examine the participants for swollen joints, assessing the 28 joints and confirm the location of the swollen joints.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>ESR will be recorded from blood samples collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>CRP will be recorded from blood samples collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject's Global Assessment of Arthritis (SGA) (visual analog scale (VAS))</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The participant assesses his/her own disease activity on a VAS of 0 - 100 mm, corresponding from 'no disease activity' to 'very severe disease activity', on the questionnaire form.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician's Global Assessment of Arthritis (PGA) (VAS)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The investigator assesses participant's disease activity on a VAS of 0 - 100 mm, corresponding from 'no disease activity' to 'very severe disease activity', on the questionnaire form.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>European League Against Rheumatism (EULAR) Response Criteria</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Based on DAS28 scores and changes in DAS28 scores before and after treatment with the study drug, EULAR Response Criteria categorize response to treatment as &quot;No response&quot;, &quot;Moderate response,&quot; or &quot;Good response.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving DAS28-CRP scores for remission</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Percentage of participants with DAS28 scores less than 2.6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving DAS28-ESR scores for remission</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Percentage of participants with DAS28 scores less than 2.6.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Peficitinib</arm_group_label>
    <description>Participants will receive peficitinib once daily after meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peficitinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>Peficitinib</arm_group_label>
    <other_name>ASP015K</other_name>
    <other_name>Smyraf</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with rheumatoid arthritis (RA) treated with peficitinib for the first
             time.

        Exclusion Criteria:

          -  Not applicable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astellas Pharma Inc.</last_name>
    <email>astellas.registration@astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site JP00023</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00012</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00038</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00018</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00040</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00007</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00021</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00010</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00034</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00028</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00008</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00017</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00037</name>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00046</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00014</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00039</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00043</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00026</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00024</name>
      <address>
        <city>Mie</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00045</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00020</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00042</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00029</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00015</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00044</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00033</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00047</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00027</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00041</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00011</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00025</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00032</name>
      <address>
        <city>Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00022</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00009</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00036</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00013</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00031</name>
      <address>
        <city>Tottori</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00016</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00030</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00035</name>
      <address>
        <city>Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site JP00019</name>
      <address>
        <city>Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-Marketing Surveillance</keyword>
  <keyword>ASP015K</keyword>
  <keyword>Smyraf</keyword>
  <keyword>Rheumatoid arthritis (RA)</keyword>
  <keyword>Peficitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

